Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 441.55K |
Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 441.55K |
Exchange | NASDAQ |
Shares Outstanding | 255.76B |
Market Cap | 66.14B |
P/E Ratio | 23.27 |
Div & Yield | N.A. (N.A) |
It’s been a hot M&A market for biotech companies developing treatments for rare diseases.
Sector may not be as bulletproof as we thought.
Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.
A Picasso Painting Fetched $179 million dollars at an auction at Christie's Monday night, the most ever paid for a work of art at auction.
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Biotech companies are saying, "I do."
Teva bid highlights M&A action in health care sector.
Teva bid highlights M&A action in health care sector.
Even the second-tier biotechs are taking off.
Here are healthcare stocks of all shares and sizes with strong charts.
We got the rally we were looking for -- so now what?
Watch the momentum names, which were the biggest positive today.
Here are several themes that are still working -- and now you can get in at a bargain.
Oracle announced Monday the purchase of Micros Systems for $5.3B and plans to combine their industry specific applications with its own.
You can always buy these names back.
After a decline, the sector has built a base, and these names are breaking out.
Spreads are wide right now, so a patient entry is required.
You don't need much conviction to trade these two names.
These types of companies are winners today.